Investigational Keto Diet Pill Shows Promise in Phase 1 Trial: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On March 5, 2025, we reported on new data from a phase 1 clinical trial examining the safety, tolerability, pharmacokinetics, and pharmacodynamics of BL-001, an investigational antiobesity medication.

The study

BL-001 (Bloom Science) is designed to replicate the metabolic effects of the ketogenic diet. The phase 1 study included 32 healthy and overweight adults.

The findings

The overall treatment effect of BL-001 on weight loss was statistically significant (P = .0424; mixed model repeated measures) with overweight participants experiencing a placebo-adjusted mean weight reduction of 2.3% (P =.001). The percent weight change between overweight and healthy-weight individuals treated with BL-001 was also statistically significant (P = .0003), with the highest recorded weight loss reaching 4.9% of body weight.

Notably, 80% of participants who lost weight on BL-001 maintained their weight loss 2 weeks after their last dose. Among overweight subjects receiving the highest dose, 100% continued losing weight, with an average 3.4% reduction at the follow-up assessment.

According to Bloom Science, the clinical data from the phase 1 study support advancing BL-001 into a phase 2 trial in adults with obesity in 2026.

Click here for more details.